Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

The following is a summary of “Improved survival in older patients with myeloid malignancies undergoing haploidentical ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

Monte Rosa announced clinical results from its MRT-6160 Phase 1, single ascending dose / multiple ascending dose study. Details about the ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Although your body will store excess vitamin A, some research shows having more than 1.5mg a day over many years may weaken ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Kate Ellis '25 took time away from classes to prioritize the needs of a leukemia patient she had never met, making a ...